Objective: Several centers have established that off-pump, multivessel coronary artery bypass grafting performed via a small thoracotomy (MVST) is feasible. However, this procedure can be challenging when posterolateral coronary targets need to be grafted. We hypothesized that use of cardiopulmonary bypass via peripheral access (MVST-PA) would improve outcomes compared with a completely off-pump approach (OP-MVST). Methods: This was a prospective observational study of patients undergoing OP-MVST (n = 46) versus MVST-PA (n = 45) using bilateral internal mammary artery grafts onto the left anterior descending coronary artery and circumflex/right coronary artery distribution. Hemostasis was quantified by measuring platelet function (aggregometry), chest tube output, thrombolysis in myocardial infarction bleeding score (%hematocrit change at 24 hours), and transfusion requirements. The rate of mortality and major morbidity at 30 days was defined according to The Society of Thoracic Surgeons criteria. Estimated glomerular filtration rate (normalized to baseline levels) was determined daily until discharge. Results: The OP-MVST versus MVST-PA groups had similar risk factors at baseline and risks of composite morbidity/mortality at 30 days. However, renal failure was significantly increased after OP-MVST (10.87 vs 0%, P = 0.05), and MVST-PA affected hemostasis as evidenced by inhibition of platelet function (latency to response on aggregometry, 29.9 vs 17.9 seconds; P = 0.04) and higher transfusion requirement (2.31 vs 0.85 units of red blood cells/patient, P = 0.04; 55.6% vs 34.8% transfused; P = 0.059). However, 24-hour chest tube output was similar (645 vs 750 mL; P = 0.53). Conclusions: In comparison with a completely off-pump strategy, use of cardiopulmonary bypass to assist MVST reduced the risk of renal dysfunction with only modest tradeoffs in other morbidities, for example, altered coagulation and higher transfusion requirements. These data justify further study of the effect of MVST-PA on renal complications.
C oronary artery bypass grafting (CABG) via sternotomy is a procedure that is highly valued for its reliability and safety. Surgical robotics enables this procedure to be performed via small incisions without a sternal incision, providing a ''less invasive'' alternative to the traditional approach. 1 Potential advantages of multivessel CABG via a small thoracotomy (MVST) include decreased risk of sternal infection and a reduction in the length of time required for postoperative recovery. In appropriate candidates, the robot can be used to procure bilateral internal mammary arteries (BIMAs) without the need for a sternotomy. Grafting these two internal mammary artery (IMA) conduits onto two different regions of the heart then provides the long-term advantages of multiarterial grafting without the risks of sternal wound infection associated with BIMA harvest. 2 This procedure is currently performed at only a few expert centers, in part because of unanswered concerns about costs, safety, and reproducibility.
Avoiding cardiopulmonary bypass (CPB) and its associated risks is another proposed advantage of MVST. 3 However, exposure and stabilization of coronary targets during MVST often pose unique challenges. The confines of a closed chest limit the working space needed for cardiac luxation compared with a full sternotomy. Excessive ventricular compression against the chest wall during these cases increases the risks for hypotension/vasopressor use, poor hemodynamics, reduced tissue perfusion, and renal dysfunction. 4 It is important to avoid this latter problem because even modest changes in renal function have demonstrated potent effects on morbidity and mortality after CABG. 5Y8 Others 9,10 have suggested that CPB support (ie, ''pump assistance'') increases the feasibility and improves outcomes for beating heart CABG. We hypothesized that MVST using pump assistance (MVST-PA) would facilitate revascularization on posterior coronary targets and improve outcomes compared with a completely off-pump approach (OP-MVST).
METHODS

Patient Selection
The institutional review board approved this prospective, observational study of patients undergoing CABG at our institution. All patients enrolled in this study provided informed consent; informed consent was not waived for any patients enrolled. Inclusion criteria for this study were patients undergoing MVST using bilateral IMA conduits between March 2008 and March 2010 without preexisting renal failure (defined by baseline creatinine level 94.0 mg/dL or dialysis requirement). If all the coronary lesions that were present could not be addressed with this approach, then they were evaluated by two staff cardiologists and deemed suitable for percutaneous coronary intervention (PCI)/stenting. Patients treated during the study interval who underwent single-vessel IMA grafting (n = 73) or sternotomy CABG (n = 82) or who had preexisting dialysis dependence before surgery or a baseline estimated glomerular filtration rate (eGFR) less than 15 mL min j1 1.73 m j2 (n = 3) were excluded. Baseline data were acquired in all patients, including whether CABG was performed within 5 days of preoperative cardiac catheterization or clopidogrel administration.
Surgical Procedure
After securing one-lung ventilation, both IMA were harvested using a skeletonized technique with robotic assistance (Intuitive Surgical, Mountain View, CA USA) and CO 2 insufflation at 8 to 10 mm Hg. Distal anastomoses were completed manually via small thoracotomy without the use of shunts. All cases were completed on the beating heart using stabilizing devices (Medtronic, Inc, Minneapolis, MN USA) without aortic cross clamping. Patients underwent MVST-PA instead of OP-MVST based on anatomic considerations about how difficult it would be to expose the necessary coronary targets. Cardiopulmonary bypass was initiated in these cases via peripheral access using femoral (or axillary) artery and vein cannulation. Site of peripheral access was based on surgeon preference using femoral (or axillary) artery and vein cannulation. Details of the perfusion strategy used by our group have been published previously. 9 No patient required an intraaortic balloon pump to be placed. If a hybrid strategy was used, PCI was performed in a separate setting using 6F guiding catheters with predilation and postdilation of coronary lesions left to the discretion of the operator. Drug-eluting stents were implanted in all patients. All patients received aspirin and clopidogrel, which were given before PCI (300 mg followed by 75 mg daily thereafter). Serial assessments of temperature, arterial blood gas, and hematocrit were prospectively collected for each case.
Management of Hemodynamics
Intraoperative hemodynamics were monitored by serial evaluation of cardiac function using transesophageal echocardiography, cerebral oximetry (INVOS, Somanetics, Troy, MI USA), and invasive monitoring of arterial and central venous blood pressure with PA catheters used selectively as described. 10 Hypotension (defined as a 20% decrease from baseline mean arterial pressure, taken after intravenous preload administration) was treated with phenylephrine boluses (10Y50 Kg) followed by an infusion (10 Kg min j1 ) in the presence of normal cardiac output. Evidence of low cardiac output with sufficient preload was treated with infusions of epinephrine and/or nor-epinephrine (0.1Y1.0 Kg kg j1 min j1 ). Transfusions were provided according to a previously published algorithm. 11 
Renal Function Assessment
The eGFR was calculated from the standard serum creatinine level expressed in mg/dL (sCr) using Modification of Diet in Renal Disease formula 12 : (175) Â (sCr j1.154 ) Â (age j0.203 ) Â (1.212, if African American) Â (0.724, if female) = GFR (in mL/ min/1.73m 2 ), where sCr is expressed in mg/dL. Urine output was monitored hourly in the first 24 hours and then daily for 4 days. Changes in eGFR during the postoperative period were quantified by the slope of eGFR change on a given postoperative day as compared with preoperative eGFR using the equation: [(GFR postop j GFR preop )/GFR preop )]. Preoperative renal dysfunction was classified as normal (GFR 990 mL min j1 1.73 m j2 ), mild (GFR of 60Y89 mL min j1 1.73 m j2 ), moderate (GFR of 30Y59 mL min j1 1.73 m j2 ), and severe (GFR of 157Y29 mL min j1 1.73 m j2 ). Preoperative renal failure was classified as GRF less than 15 mL min j1 1.73 m j2 or creatinine level greater than 4.0 mg/dL (or otherwise requiring dialysis).
Adverse Outcomes
The following prospectively defined outcomes were compared between cohorts: Risk adjusted major and minor complications until 30 days, using The Society of Thoracic Surgeons National database definitions. 13, 14 Major adverse cardiac and cerebrovascular events (MACCEs) during the first year, using the Arterial Revascularization Therapies Study 1 definition. 15 Renal insufficiency was defined using the following criteria: risk of renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney function, and end-stage kidney disease. 16 This is defined as renal injury when postoperative eGFR is less than 75% of baseline and renal failure when eGFR is less than 50% of baseline or more than 75% combined with urine output less than 0.5 mL kg j1 h j1 for more than 6 hours. Poor hemostasis and bleeding as quantified by mean 24-hour chest tube output measurements, mean thrombolysis in myocardial infarction (TIMI) bleeding score, 17 and transfusion requirement defined by mean number units of blood transfused per patient and frequency of transfusions in each cohort.
Platelet Aggregometry
Whole blood aggregometry (Chronolog, Hawerton, PA USA) was performed using previously described techniques, 11 and impedance change (6) was assessed in platelet-rich plasma at 6 minutes after the addition of a series of agonists: (1) adenonsine diphosphate (5 and 10 mM), and (2) collagen (1 and 5 g/mL). Stimulation and complete blood counts were performed at baseline, immediately after surgery, and on postoperative day (POD) 1. Values obtained were total change in impedance ($6), area under the curve of 6, slope of the curve of 6 versus time (ie, rate of aggregation), and time between platelet stimulation and initial response (ie, latency).
Statistical Analysis
Using renal failure as a sensitive indicator of compromised intraoperative perfusion, our power analysis demonstrated that a minimum sample size of 52 (26 patients per group) was required at a power level of 0.8 to determine hypothesized differences between groups. Comparisons were done by analysis of variance with subsequent pairwise comparisons according to the Duncan multiple range test and correlations determined by calculating a Pearson coefficient. Categorical data were compared using the Fischer exact test. Logistic regression was used to determine an interaction between study group assignment (ie, OP-MVST vs MVST-PA) and previously reported risk factors for renal failure. Variables with P less than 0.1 between groups with and without acute kidney injury were included in a stepwise fashion in the model. Analyses were performed with SPSS statistical software (SPSS version 13.0; SPSS, Chicago, IL) and SAS (SAS version 9.1; SAS, Cary, NC) with the assistance of a statistician.
RESULTS
Study Groups
A total of 91 MVST procedures using BIMA grafts were performed by a single surgeon at our institution during the study interval. The distribution of cases was even between MVST-PA (n = 45) and OP-MVST (n = 46), although group assignment was not randomized. One patient in each group required conversion to a sternotomy incision because of in-ability to tolerate single-lung ventilation. Three patients who were in the OP-MVST group required pump assistance because of intraoperative hemodynamic instability. These cases were included in the OP-MVST group according to an intention-to-treat principle. The findings of our study were not altered when a separate analysis was performed after including these three patients in the MVST-PA group. Each was evaluated with the intention-to-treat principle. No patients required reoperation for revascularization. Baseline characteristics and preoperative use of medications were similar between the two groups ( Table 1) , except that patients with diabetes had significantly higher mean hemoglobin A1c preoperatively in the MVST-PA cohort (7.26% vs 6.46%; P = 0.02). There was no difference in the proportion of patients having received cardiac catheterization within 5 days of CABG (19.1% vs 17.7; P = 1.00) or who were on angiotensin converting enzyme inhibitors/ angiotensin-II receptor blockers (57.8% vs 43.9%; P = 0.280). There was no significant difference in either preoperative renal function or distribution of patients among classes of preoperative renal dysfunction between groups (data not shown). There was a similar incidence of chronic lung disease (15.2% vs 14.3%; P = 1.00), cerebrovascular disease (10.9% vs 11.9%; P = 1.00), congestive heart failure (28.3% vs 28.6%; P = 1.00), previous stroke or transient ischemic attack (0.0% vs 2.8%; =1.00), and atrial fibrillation (11.4% vs 5.1%; P = 0.439). There were no differences in preoperative mean arterial pressures among groups (99.96 vs 98.30 mm Hg; P = 0.571). No patients had a previous intraaortic balloon pump placed. The mean logistic EuroScore was similar between the MVST-PA and the OP-MVST group (7.18 T 8.47 vs 6.39 T 6.25, respectively; P = 0.616).
Intraoperative Variables
Including the period of CPB support, for the MVST-PA cohort, this group showed lower mean systolic (80.6 vs 111.3 mm Hg; P G 0.001) and diastolic (54.4 vs 59.0 mm Hg; P = 0.04) pressure than the OP-MVST group did. This difference did not increase the need for vasopressors. On the contrary, the OP-MVST group showed a significantly greater intraoperative use of phenylephrine and a trend toward increased use of epinephrine/norepinephrine (Table 2) , often triggered by hypotension after cardiac manipulation to expose coronary targets off-pump. Total operating room (OR) time and the number of bypass grafts placed were similar between groups ( Table 2) . During MVST-PA, arterial PO 2 was significantly lower than during OP-MVSTat the completion of BIMA harvest (198.16 vs 283.32 mm Hg; P G 0.001) and during the distal anastomoses (182.13 vs 328.42 mm Hg; P G 0.001) but not by the end of the case. Mean PCO 2 and temperature were similar between groups at all three time points. Although mean intraoperative central venous pressure was similar between groups, peak central venous pressure (often during periods of cardiac manipulation) was higher in the OP-MVST group (21.31 T 9.91 vs 13.28 T 5.99; P G 0.001).
Postoperative Clinical and Renal Outcomes
The risk of the composite endpoint of major morbidity and mortality within 30 days was similar between groups (8.9% vs 13.0%; P = 0.739) ( Table 3 ) and consistent with the predicted risk according to The Society of Thoracic Surgeons risk model (observed to expected ratio, 0.9 vs 1.1; P = 0.09). Over the first postoperative year, both groups had a similar risk of MACCEs (8.7 vs 8.9%, P = 1.00) ( Table 3 ) and need for repeat revascularization (4.3% vs 4.4%; P = 1.0). There was no significant difference in postoperative length of stay between the two groups (5.89 vs 6.19 days; P = 0.787). Patients in the MVST-PA group had a significantly longer stay in the intensive care unit (41.6 vs 66.1 hours; P = 0.004) and remained on ventilation longer (20.9 vs 10.5 hours; P = 0.019).
No patient required dialysis postoperatively. On POD 2, OP-MVST had a significantly higher instance renal failure (10.87% vs 0%; P = 0.055, W 2 ) and a trend toward significance in the risk of renal injury (15.91% vs 6.98%; P = 0.314). The OP-MVST group showed lower urine output intraoperatively (490.2 vs 796.0 mL; P G 0.001) and over the first 24 hours (2151.0 vs 2719.0 mL; P G 0.001). Although eGFR was similar between groups at baseline (72.3 vs 73.2 mL min j1 1.73 m j2 ), it declined over the next 2 days after OP-MVST but not MVST-PA (change from baseline: j3.1% vs +11.5%; P = 0.028) ( Fig. 1 ). Neither postoperative renal injury nor failure showed any relationship to MACCE at 1 year in this cohort.
Compared with those without renal failure (n = 80), patients with postoperative renal failure (n = 4) had longer postoperative length of stay (9.25 vs 5.45 days; P G 0.011) and were more likely to be discharged to transitional care unit/rehabilitation rather than home (75.0 vs 21.8% discharged to transitional care unit/rehabilitation; P = 0.043). Renal failure patients were more likely to be readmitted to the intensive care unit (50.0% vs 1.4%; P = 0.006) but showed no increase in readmission to the hospital after discharge (14.6% vs 20.0%; P = 0.564). Independent predictors of renal injury on POD 2 in a multivariate model included preoperative peripheral vascular disease (P = 0.02), active smoking (P = 0.03), and the intraoperative use of epinephrine/norepinephrine (P = 0.02) but not assignment to OP-MVST versus MVST-PA.
Predictors of Renal Function
Hemostasis/Bleeding
Intraoperatively, MVST-PA patients had a lower hemoglobin level at the completion of the case (9.82 vs 11.58 g/dL; P G 0.001) and received significantly more blood transfusions FIGURE 1. Comparison of urine output and eGFR versus time (OP-MVST vs MVST-PA). Renal function was followed during hospitalization in terms of mean urine output (A) and mean eGFR (B) during and after the operative period. Urine output was significantly greater after MVST-PA at all time points other than POD 2. Although the absolute eGFR was not different between groups, there was a significant difference in the change from baseline between groups on POD 2 (j3.1% vs 11.5%; P = 0.028). Error bars represent standard error. *P G 0.05. eGFR indicates estimated glomerular filtration rate; MVST, multivessel coronary artery bypass grafting performed via a small thoracotomy; OP, off-pump; PA, peripheral access; POD, postoperative day 2.
(0.89 vs 0.23 units of red blood cells/patient; P = 0.03). Over the first 24 hours after surgery, bleeding was similar between groups (chest tube output, 645 vs 750 mL, P = 0.53; TIMI bleeding score, 10.0 vs 8.7, P = 0.31), but the total transfusion requirement was higher after MVST-PA (2.31 vs 0.85 units of red blood cells/patient, P = 0.04; 55.6 vs 34.8% of cohort transfused, P = 0.059). There was no significant difference in the number of patients who underwent repeat operation for bleeding between the groups (2.2% vs 6.7%; P = 0.361) nor for revascularization (3.0% vs 0.0%; P = 1.00). On POD 1, platelet counts declined in both groups (34.8% vs 27.9% decline from baseline; P = 0.06), although platelet function measured by aggregometry appeared to be better preserved after OP-MVST (latency to response to adenonsine diphosphate, 17.9 vs 29.9 seconds, P = 0.04; 42% vs 84% prolongation compared with baseline, P = 0.03). The proportion of patients having undergone PCI within 5 days of surgery was similar between both groups (17.4% vs 20.5%, P = 0.791). There was no significant difference in the proportion of patients who received preoperative clopidogrel (17.4% vs 24.4%; P = 0.449). Those patients who received preoperative clopidogrel showed no significant difference in transfusion requirement, TIMI risk stratification, preoperative or postoperative platelet levels, and chest tube output compared with those on active therapy.
DISCUSSION
Using the sternotomy approach, BIMA grafting involves a tradeoff between the short-term infection risks and long-term patency. Multivessel CABG via a small thoracotomy with BIMA grafts provides comparable results with traditional CABG in terms of patency and long-term outcomes while eliminating the risk of sternal infection. 18, 19 This study analyzed outcomes after MVST that involved BIMA grafts placed onto inferior and posterior targets. The rates of complications, myocardial injury, and most postoperative problems were acceptable in comparison with expected outcomes for traditional CABG. However, renal failure was an unanticipated problem after OP-MVST. This adverse event was associated with intraoperative hypoxia and the need for inotropes and/or vasopressors and/or intravenous contrast use (eg for heart catheter-ization) within 5 days of surgery. In these cases, CPB assistance was associated with significantly reduced renal complications, perhaps by rapidly and effectively mitigating hypoxia and the need for inotropes and pressors during revascularization. There has been a strong association noted between even modest changes in postoperative renal function and the risks of mortality and excessive resource utilization and costs after CABG. 20 Despite tradeoffs of longer OR times, greater blood loss, and more perioperative transfusions, CPB assistance might promote broader application of MVST, and we feel that these results warrant further study In retrospect, it may seem obvious that prolonged cardiac luxation within the closed chest without the support of CPB would lead to problems with hemodynamics and renal perfusion. Our adoption of CPB in these cases reflects the ''trial and error'' process that accompanies procedures with limited acceptance and no ''best practices'' established a priori from which we could draw. We were initially reluctant to use CPB because previous data have suggested that off-pump CABG is renoprotective. 21 It is thought that CPB injures kidney function by inducing hemodilution, activation of inflammatory and clotting cascades, nonpulsatile perfusion, hemolysis, and release of nephrotoxic free hemoglobin. 22 It is possible that our strategy of using a miniaturized, heparin-coated CPB circuit without cardiotomy suction, maintaining pulsatile blood flow during CPB support and avoiding the sternotomy, helped mitigate these problems traditionally associated with CPB. In the absence of a third MVST group supported with a traditional CPB circuit for comparison, this point remains speculative and requires further study. Furthermore, hemodilution may be a mechanism by which serum creatinine levels may have been artificially lower in the MVST-PA group. However, we felt that the differences observed in creatinine were too great to be explained by hemodilution alone. In addition, differences in renal function were observed as far as 2 days postoperatively, including a decrease in urine output in the OP-MVST group.
It is not uncommon for patients requiring coronary revascularization to have preexisting renal disease. Off-pump CABG via a sternotomy has been shown to reduce the risk of adverse outcomes and renal injury in these patients compared with percutaneous techniques (PCI). 23 However, our findings illustrate that off-pump may not always be renoprotective. Variability in outcomes are often derived from unpredictable hemodynamics during off-pump CABG, particularly in the case of emergency conversion from off-to on-pump CABG. Several studies have demonstrated that on-pump conversion triggers a variety of complications including renal injury. 24Y29 Initiating CPB during MVST requires peripheral cannulation, a procedure that takes longer than direct intracardiac cannulation through the open chest. Therefore, emergency conversion from off-to on-pump MVST can be associated with extended periods of poor tissue perfusion. Additional studies aimed at identifying those MVST cases most likely to derive benefit from CPB may help maintain the renoprotective advantages of surgery over PCI.
Renal function after MVST is influenced by anesthesia management, which can be highly challenging. These cases combine the more complex management issues associated with off-pump CABG (eg, cardiac luxation and temporary coronary artery occlusion) 30 and thoracoscopic surgery (eg, intrathoracic CO 2 insufflation and single-lung ventilation). 31, 32 Moreover, the time required for BIMA harvesting prolongs the period before revascularization in which these challenges are able to provoke cardiopulmonary problems if not effectively managed.
In our patients, we noted that a low PO 2 level at the completion of BIMA harvest was a predictor of renal injury. A unique issue with BIMA harvest during MVST is that the right pleura is opened when procuring the right IMA, which exposes the univentilated right lung to CO 2 insufflation pressures (10Y12 mm Hg). Positive ventilator pressure after expiration (ie, positive endexpiratory pressure) was not routinely used in most of these cases. As a result, there was a risk of compressing the ventilated lung and compromising oxygenation during thoracic insufflation. We speculate that, depending on the patients'degree of preexisting renal tolerance to hypoxia, intraoperative hypoxia might help explain the high rate of postoperative renal injury seen in the OP-MVST group and believe that this warrants further study. An important limitation of this study is that it was not a randomized trial but reflects ongoing efforts at process improvement. On the basis of the intention-to-treat principle, the OP-MVST group included three patients who required emergent conversion to CPB support. Excluding these three patients from the analysis did not alter the main findings of our study. Because the study groups were treated with significantly different volumes of fluid in the OR, the use of serum creatinine to compare renal function is another methodological problem with this study. We normalized creatinine to baseline levels and to age, sex, and body surface area by calculating eGFR to minimize the influence of fluid management. In addition, abnormalities measured in eGFR were significantly associated with lower urine output, corroborating the pathologic significance of the creatinine differences between groups. In addition, the sample size of our study was not adequate to assess differences of rare adverse outcomes (eg, stroke). To determine differences in incidence of stroke, a minimum sample size of 788 (394 per group) would be required at the 0.8 power level. We feel that this is an acceptable limitation because these outcomes were not primary endpoints of our study; however, they do warrant further investigation. A final limitation of this study is that it was not sufficiently powered to establish longterm efficacy.
CLINICAL PERSPECTIVE
This is a prospective, observational study comparing 46 patients undergoing off-pump multivessel small thoracotomy coronary artery bypass grafting to 45 patients undergoing the same procedure using cardiopulmonary bypass (CPB) via peripheral access. In this small series, the use of CPB significantly reduced the incidence of renal failure from 11% to 0%. There was a modest tradeoff with a not unexpectedly higher transfusion requirement in the patients placed on CPB. The important limitations of this study are the groups were small and not randomized. Therefore, there may have been a significant selection bias. Moreover, the incidence of renal failure in the off-pump group was higher than in previous reports. In fact, some centers have advocated this approach in patients with renal dysfunction as being more friendly to the kidneys than going on CPB. This small study is underpowered to detect other differences in morbidity between the two techniques. However, this is an interesting report and suggests the need for larger, randomized studies comparing these two operative strategies.
